2021 Nov: Die eerste kliniese proef van Suid-Korea se tuisgemaakte volgende generasie chimeriese antigeenreseptor T (CAR-T) selterapie, wat ontwerp is om immuunkontrolepuntseine te omseil, het onlangs aan die gang gekom.
Die Korea Advanced Institute of Science and Technology (KAIST) het Woensdag aangekondig dat 'n Fase 1b-kliniese proef van sy CAR-T-selterapie tans by die Samsung Mediese Sentrum in Seoul uitgevoer word. Die verhoor word uitgevoer met 10 Koreaanse pasiënte wat terugval en refraktêre diffuse groot B-sel limfoom het. Die bemarkingsregte vir die pyplyn is oorgedra van die universiteit na die maatskappy Curocell, wat mede-stigter is deur professor Kim Chan-hyuk. Curocell is in beheer van die kliniese ontwikkelingsprogram van die revolusionêre immunotherapie.
In addition, a Phase 2 kliniese proef involving seventy participants is going to take place the following year to assess how safe and effective the investigational medication is.
The acronym CAR T, which stands for chimere antigeen reseptor T, is frequently referred to as a miracle cure. This is due to the fact that studies conducted in other countries on terminal blood cancer patients demonstrated that the therapy had a therapeutic effect of more than 80 percent. T cells from a patient are taken from the patient’s blood, genetically enhanced to make them more effective, and then reintroduced to the patient so that they can continue to fight and destroy cancer cells inside the patient’s body.
The research team that was led by Professor Kim of the Department of Biomedical Engineering at the KAIST confirmed an improved anticancer efficacy of CAR-T cells in mice with leukaemia and lymphoma. This was achieved by simultaneously inhibiting programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and ITIM domain (TIGIT), both of which are known to disturb the function of T cells. According to Professor Lee Young-ho, a post-doctoral researcher at KAIST and the first author of the animal model study, this dual blockade of PD-1 and TIGIT is a novel strategy to overcome the immunosuppression of existing CAR-T cells. This strategy was discovered by Prof. Lee Young-ho.
U wil dalk lees: CAR T-Cell terapie in Korea
Die bevindinge van die studie is aangebied in 'n artikel wat aanlyn in die Oktober-uitgawe van Molecular Therapy gepubliseer is.
